Understanding the mode of action of PDAC targeted drugs (P18)

了解PDAC靶向药物的作用方式（P18）

• 批准号: 404526486
• 金额: --
• 依托单位: Lehrstuhl für Proteomik und Bioanalytik / Experimentelle Bioinformatik
• 依托单位国家: 德国
• 项目类别: Collaborative Research Centres
• 财政年份: 2018
• 资助国家: 德国
• 起止时间: 2017-12-31 至 2022-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/404526486?language=en
• 关键词: Understanding; mode; action; PDAC; targeted

We will apply our newly developed proteomic technology termed decryptM that characterizes the effects of mutant KRAS targeted drugs on the proteome and phospho-proteome of cellular and animal models of PDAC in a fully time- and dose-dependent fashion. Covering 10,000 proteins, 20,000 phosphorylation sites, 2,000 acetylation sites and 5,000 ubiquitinylation sites in parallel will yield unprecedented pharmacodynamic information regarding drug target engagement, distinguish the main mechanism of action (MoA) from lesser drug effects, and shed light on drug adaptation or resistance mechanisms.

我们将应用我们新开发的称为解密M的蛋白质组技术，该技术以完全时间和剂量依赖性的方式表征突变型KRAS靶向药物对PDAC细胞和动物模型的蛋白质组和磷酸化蛋白质组的影响。并行覆盖 10,000 个蛋白质、20,000 个磷酸化位点、2,000 个乙酰化位点和 5,000 个泛素化位点将产生有关药物靶点参与的前所未有的药效学信息，区分主要作用机制 (MoA) 和较小的药物作用，并揭示药物适应或耐药机制。